» Articles » PMID: 11753675

Inhibition of Constitutively Active Stat3 Suppresses Growth of Human Ovarian and Breast Cancer Cells

Overview
Journal Oncogene
Date 2001 Dec 26
PMID 11753675
Citations 109
Authors
Affiliations
Soon will be listed here.
Abstract

Signal transducers and activators of transcription (STATs) are transcription factors activated in response to cytokines and growth factors. Constitutively active Stat3 has been shown to mediate oncogenic transformation in cultured cells and induce tumor formation in mice. An increasing number of tumor-derived cell lines as well as samples from human cancer have been reported to express constitutively active Stat3 protein. We previously demonstrated that ovarian cancer cell lines express high levels of constitutively active Stat3. In this study, we show that inhibition of the Stat3 signaling pathway using the Janus Kinase-selective inhibitor, AG490, and a dominant negative Stat3 (Stat3beta) significantly suppresses the growth of ovarian and breast cancer cell lines harboring constitutively active Stat3. In the ovarian cancer cell lines, AG490 also diminished the phosphorylation of Stat3, Stat3 DNA binding activity, and the expression of Bcl-x(L). Further, AG490 induced significant apoptosis in ovarian and breast cancer cell lines expressing high levels of constitutively active Stat3 but had a less profound effect on normal cells lacking constitutively active Stat3. AG490 also enhanced apoptosis induced by cisplatin in ovarian cancer cells. These results suggest that inhibition of Stat3 signaling may provide a potential therapeutic approach for treating ovarian and breast cancers.

Citing Articles

Naringenin induces ferroptosis in osteosarcoma cells through the STAT3-MGST2 signaling pathway.

Li Y, Bai X J Bone Oncol. 2025; 50():100657.

PMID: 39835176 PMC: 11743371. DOI: 10.1016/j.jbo.2024.100657.


Co-Inhibition of tGLI1 and GP130 Using FDA-Approved Ketoconazole and Bazedoxifene Is Synergistic Against the Growth and Metastasis of HER2-Enriched and Triple-Negative Breast Cancers.

Manore S, Zhuang C, Najjar M, Wong G, Bindal S, Watabe K Cells. 2025; 13(24).

PMID: 39768178 PMC: 11674475. DOI: 10.3390/cells13242087.


Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study.

Landen C, Buckanovich R, Sill M, Mannel R, Walker J, DiSilvestro P J Clin Oncol. 2024; 42(21):2537-2545.

PMID: 38776484 PMC: 11551860. DOI: 10.1200/JCO.23.02076.


Therapeutic Potential of Protein Tyrosine Kinase 6 in Colorectal Cancer.

Jerin S, Harvey A, Lewis A Cancers (Basel). 2023; 15(14).

PMID: 37509364 PMC: 10377740. DOI: 10.3390/cancers15143703.


Enhancement of PD-L1-attenuated CAR-T cell function through breast cancer-associated fibroblasts-derived IL-6 signaling via STAT3/AKT pathways.

Chuangchot N, Jamjuntra P, Yangngam S, Luangwattananun P, Thongchot S, Junking M Breast Cancer Res. 2023; 25(1):86.

PMID: 37480115 PMC: 10362675. DOI: 10.1186/s13058-023-01684-7.